ADINA Act — HR. 3821

TL;DR (AI)

• This bill amends the Federal Food, Drug, and Cosmetic Act to require labels on drugs intended for human use to disclose ingredients derived from major food allergens or gluten-containing grains.
• A drug is considered misbranded if it contains such ingredients and the label fails to disclose them, specifying the ingredient and, if applicable, the type of gluten-containing grain.
• The labeling requirements will take effect either two years after the Act's enactment or at a date determined by the Secretary of Health and Human Services.